What is Zacks Research's Forecast for Glaukos Q3 Earnings?

Key Points

• Zacks Research has reduced Glaukos' Q3 2026 earnings estimate from $0.03 to $0.02 per share and currently holds a "Hold" rating on the stock.
• Glaukos reported a quarterly loss of ($0.24) EPS, exceeding analyst expectations, with revenue of $124.12 million, reflecting a year-over-year increase of 29.7%.
• Multiple brokerages have set diverse target prices for Glaukos, with UBS Group raising its target from $125.00 to $134.00 and maintaining a "buy" rating.

Glaukos Corporation (NYSE:GKOS - Free Report) - Zacks Research cut their Q3 2026 earnings per share (EPS) estimates for Glaukos in a research note issued to investors on Wednesday, August 20th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.02 per share for the quarter, down from their prior estimate of $0.03. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos' Q4 2026 earnings at $0.09 EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.29 EPS and FY2027 earnings at $0.93 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The company had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. During the same quarter in the prior year, the company earned ($0.52) earnings per share. Glaukos's revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS.

Other research analysts also recently issued research reports about the company. Truist Financial reaffirmed a "buy" rating and issued a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. Wells Fargo & Company raised their price objective on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Mizuho set a $130.00 price objective on Glaukos in a research note on Thursday, July 31st. Stephens decreased their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Finally, Needham & Company LLC decreased their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Stock Performance

GKOS stock traded down $0.70 during trading on Monday, reaching $95.86. The stock had a trading volume of 488,453 shares, compared to its average volume of 846,228. Glaukos has a 52 week low of $77.10 and a 52 week high of $163.71. The stock's 50 day moving average is $95.62 and its two-hundred day moving average is $99.48. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The firm has a market cap of $5.50 billion, a PE ratio of -58.10 and a beta of 0.78.

Institutional Trading of Glaukos

Several institutional investors have recently made changes to their positions in the business. Thrivent Financial for Lutherans grew its position in shares of Glaukos by 3.7% during the second quarter. Thrivent Financial for Lutherans now owns 42,017 shares of the medical instruments supplier's stock worth $4,340,000 after purchasing an additional 1,518 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in Glaukos by 11.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 194,842 shares of the medical instruments supplier's stock valued at $20,125,000 after buying an additional 20,006 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Glaukos by 1.7% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 60,834 shares of the medical instruments supplier's stock valued at $6,290,000 after buying an additional 1,000 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Glaukos by 367.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,804 shares of the medical instruments supplier's stock valued at $599,000 after buying an additional 4,562 shares in the last quarter. Finally, Corient Private Wealth LLC grew its holdings in Glaukos by 5.8% during the 2nd quarter. Corient Private Wealth LLC now owns 31,625 shares of the medical instruments supplier's stock valued at $3,267,000 after buying an additional 1,728 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.